Cytori to add cancer drugs, nanoparticle tech in Azaya deal

Handshake
Cytori thinks the acquited platform will enable delivery of regenerative medicines

Cytori Therapeutics is set to gain cancer drugs and a liposomal nanoparticle technology platform through the acquisition of Azaya Therapeutics. The lead drug is a formulation of doxorubicin, the active ingredient in Johnson & Johnson’s off-patent ovarian cancer drug Doxil.

San Diego, CA-based Cytori thinks the lead program, ATI-0918, could come to market in Europe in 2019. That timeline assumes Cytori starts manufacturing preparations upon closing the takeover and goes on to file for approval early next year on the strength of a bioequivalence trial comparing ATI-0918 to Doxil. Cytori is weighing up whether to run a new study comparing ATI-0918 to the U.S. reference drug, Sun Pharma’s Lipodox.

The plan is to partner ATI-0918 to gain a quick return on the Azaya buyout without having to build out a commercial operation in Europe. Cytori is paying little upfront for this opportunity and other assets, but the value of the deal swell to upward of $160 million if assorted milestones and royalty payments are triggered.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

Exactly how much Cytori ends up paying will depend on the progress of the assets it is buying from Azaya. The other cancer drug, ATI-1123, is a nanoparticle-stabilized liposomal formulation of docetaxel Azaya tested in a 29-person phase 1 solid tumor trial. On the strength of data from that trial, Cytori plans to work with partners on phase 2 studies of the candidate in multiple indications.

The two cancer drugs give Cytori near-term opportunities but sit outside of its core focus, namely regenerative medicines. Cytori expects this side of the business, the centerpiece of which is the experimental cell therapy Habeo, to benefit from Azaya’s liposomal nanoparticle technology platform.

“Azaya’s technology and intellectual property present an exciting opportunity to marry Cytori’s cell therapy technology, which is currently in late-stage clinical trials, to a clinically proven and patented off-the-shelf pharmaceutical delivery system directly applicable to regenerative medicine,” Cytori CEO Marc Hedrick said in a statement.

Cytori hopes to use the platform to deliver regenerative medicines to sites affected by acute or chronic injuries.

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.